Medicare Insights

Medicare Advantage in 2027: The Market Is Stable Nationally, but Changing County by County

What insurance agents need to know about carrier exits, local plan availability, prescription drug costs, premiums and the changing Medicare landscape.

Freedom Marketing Group 12 min read
An insurance advisor helping an older couple review Medicare coverage options on a laptop

The 2027 Medicare Advantage market has two stories happening at the same time.

At the national level, the outlook appears relatively stable. The Centers for Medicare & Medicaid Services (CMS) projects that the weighted average monthly Medicare Advantage premium will decrease from $14.37 in 2026 to $12.00 in 2027. CMS also estimates that approximately 34 million people will be enrolled in Medicare Advantage in 2027.

But the national numbers do not tell the entire story.

A recent KFF analysis of 2027 Medicare plan data found that major insurers are withdrawing from hundreds of counties, the number of beneficiaries with access to more than 40 Medicare Advantage drug plans is declining, and 193 counties will have no Medicare Advantage plans with prescription drug coverage available for general enrollment.

At the same time, prescription drug costs, plan deductibles and quality ratings are creating new considerations for beneficiaries and the agents who help them compare coverage.

For Medicare insurance agents, this means 2027 is not simply about finding more people interested in Medicare. It is about understanding what is actually available in a beneficiary's county, identifying why someone is reviewing coverage and helping them compare the details that matter.

Here is a closer look at the latest Medicare Advantage trends for 2027 and what they mean for insurance agencies.

2027 Medicare Market: The Numbers Agents Should Know

Before looking at individual market changes, consider the latest national figures.

Market indicator2027 outlook
Projected Medicare Advantage enrollment34 million
Share of Medicare enrollment in Medicare Advantage47.4%
Weighted average monthly MA premium$12.00
Weighted average monthly MA premium in 2026$14.37
Beneficiaries with access to at least one MA planMore than 99%
Beneficiaries with access to 10 or more MA plan choices97%
Total MA plans projected by CMSApproximately 5,532
Average MA-PD options available per beneficiary in KFF analysis28

Sources: CMS 2027 Medicare Advantage and Part D outlook and KFF's 2027 Medicare Advantage plan availability analysis.

These numbers describe different parts of the market. CMS's national figures cover its broader Medicare Advantage projections, while KFF's county-level analysis focuses specifically on Medicare Advantage prescription drug plans (MA-PDs) and excludes several other plan categories.

That distinction matters. A national plan count does not tell an agent which carriers operate in a particular county or which plans are suitable for an individual beneficiary.

1. Medicare Advantage Plan Availability Is Becoming More Local

One of the most important Medicare Advantage trends for 2027 is the difference between national plan availability and local plan availability.

According to KFF's November 2026 analysis:

  • 20% of Medicare beneficiaries can choose from more than 40 MA-PD options in 2027.
  • That share was 27% in 2026.
  • The average beneficiary has access to approximately 28 MA-PD options.
  • Nearly 7 million beneficiaries have access to only 1–10 MA-PD options, up from 4.8 million in 2026.

This does not mean Medicare Advantage is disappearing. It means the distribution of plan choices is changing.

A beneficiary in one county may have dozens of Medicare Advantage plans to compare, while someone in another county may have a much smaller selection.

193 counties will have no general-enrollment MA-PD options

KFF found that 193 counties will have no Medicare Advantage plans with prescription drug coverage available for general enrollment in 2027. These counties account for approximately 638,000 Medicare beneficiaries, or around 1% of the Medicare population.

For comparison, 123 counties were in this position in 2026.

There is an important qualification: this does not mean all Medicare coverage is unavailable in those counties. Original Medicare remains an option, and certain counties may have other private plan types, including Medicare Advantage-only plans, cost plans or Special Needs Plans with specific eligibility requirements.

For agents, the practical lesson is clear: never assume that a plan available in one county is also available in a neighboring county.

Before discussing coverage, verify the beneficiary's actual service area and the plans offered there.

2. Major Medicare Advantage Insurers Are Reshaping Their County Footprints

Another important development is how major insurance companies are changing where they offer Medicare Advantage prescription drug plans.

KFF's analysis of CMS's 2026 and 2027 plan landscape files identified substantial county-level changes.

Insurance organizationCounties exitingCounties entering
UnitedHealth Group2289
Humana624
Health Care Service Corporation4980
Centene35915
Devoted Health0342
CVS Health18663

Source: KFF analysis of CMS 2026 and 2027 Medicare Advantage plan landscape files.

These figures refer to changes in the counties where the organizations offer MA-PD plans. They do not mean that every organization is leaving Medicare Advantage nationally or withdrawing all of its insurance products.

KFF also reports that Group 1001, which markets plans under the Clear Spring Health name, and Molina Healthcare are exiting the MA-PD market. Molina continues to offer Special Needs Plans in many counties.

Meanwhile, Devoted Health is expanding its MA-PD footprint into 342 counties.

Why this matters to Medicare agents

Carrier changes can create important questions for existing and prospective clients:

  • Is the beneficiary's current plan available for 2027?
  • Is the current insurer continuing to serve the county?
  • Are the beneficiary's preferred doctors and hospitals still in-network?
  • Are their prescriptions covered under the new formulary?
  • Does the beneficiary need to compare a different plan type?
  • Are there alternative plans available in the same service area?

A carrier leaving a county does not automatically mean a beneficiary has no other coverage options. However, it can create a more complicated comparison process.

Agencies should use current carrier and plan information rather than relying on last year's market assumptions.

Read the full KFF county-level Medicare Advantage analysis.

3. Medicare Advantage Premiums Are Falling Nationally, but That Is Not the Whole Cost Story

CMS projects that the weighted average monthly premium across Medicare Advantage plans will decrease from $14.37 in 2026 to $12.00 in 2027.

That represents a projected decline of approximately 16.5%.

CMS also estimates that approximately eight in ten Medicare Advantage beneficiaries will be able to remain in their current plan with the same or a lower premium in 2027.

These are encouraging national figures, but agents should be careful about how they explain them.

A lower average premium does not automatically mean lower total healthcare costs for every beneficiary.

A plan's overall cost can also depend on:

  • Annual deductibles
  • Primary care and specialist copayments
  • Hospital cost sharing
  • Prescription drug coverage
  • Coinsurance
  • Out-of-pocket maximums
  • Provider networks
  • Pharmacy networks
  • Supplemental benefit limitations

The premium is only one part of the comparison.

Medicare Advantage payments and member premiums are different measures

There is another important distinction in the 2027 market.

CMS's April 2026 Medicare Advantage rate announcement projected an average 2.48% increase in payments to Medicare Advantage plans, representing more than $13 billion. When estimated risk-score trends are included, CMS reported a 4.98% increase.

That payment projection is not the same thing as a beneficiary's monthly premium, and it should not be interpreted as a direct prediction of plan benefits or consumer costs.

The difference between plan payments, premiums and individual cost sharing is important when interpreting Medicare market headlines.

Source: CMS 2027 Medicare Advantage and Part D Rate Announcement.

4. Medicare Part D Costs Deserve More Attention in 2027

An older woman and family member reviewing prescriptions and coverage paperwork

Prescription drug coverage is another area where agents should pay close attention.

For 2027, the standard Medicare Part D deductible increases from $615 to $700.

The annual out-of-pocket threshold for covered Part D drugs increases from $2,100 to $2,400.

Once a beneficiary reaches the applicable $2,400 threshold for covered Part D drug spending, they enter catastrophic coverage and pay no additional out-of-pocket cost sharing for covered Part D drugs for the rest of that calendar year.

This is a prescription drug benefit limit. It should not be described as a cap on all Medicare healthcare expenses.

Some plans may have lower deductibles or no deductible, so the standard maximum should not be confused with the deductible of every individual plan.

Official reference: Medicare.gov — How Much Does Medicare Drug Coverage Cost?.

Why Part D premium headlines need context

There is an interesting difference between two published 2027 Part D premium estimates.

CMS projects that the average monthly premium for stand-alone Part D prescription drug plans will increase from $35.09 in 2026 to approximately $36 in 2027.

However, KFF's October 30 analysis estimates that the enrollment-weighted average premium could be $51 in 2027 if current enrollees keep their existing stand-alone drug plans.

These figures use different approaches.

KFF's $51 estimate assumes that existing enrollees remain in their current plans, using June 2026 enrollment to weight the calculation. CMS's $36 projection uses September 2026 enrollment. KFF notes that switching by existing beneficiaries and plan choices by new enrollees are likely to bring the actual average below its $51 estimate.

This is not a reason to tell every beneficiary that their Part D premium will be $51. It is a reason to understand how much plan switching can matter.

KFF also estimates that, if current non-LIS enrollees keep their existing plans, approximately 30% could face a monthly premium of $100 or more in 2027.

Source: KFF — Medicare Part D Premiums and Cost Sharing in 2027.

Deductibles and coinsurance matter as much as premiums

KFF's analysis also highlights changes in prescription drug cost sharing.

For 2027, it estimates:

  • 85% of MA-PD enrollees will be in plans with a Part D deductible, assuming current enrollees remain in their plans.
  • 99.8% of stand-alone PDP enrollees will be in plans with a deductible under the same assumption.
  • Most MA-PD and stand-alone PDP enrollees will face coinsurance rather than fixed copayments for certain preferred and non-preferred brand drugs.

Coinsurance means the beneficiary pays a percentage of the drug's cost, rather than a fixed dollar amount. Depending on the medication and plan, that can make costs less predictable.

For agents, this makes prescription reviews especially important. A plan with a low monthly premium may not necessarily be the most suitable option for someone with specific medication needs.

5. Medicare Advantage Star Ratings: What Changed for 2027?

CMS published the 2027 Medicare Advantage and Part D Star Ratings on October 8, 2026.

These ratings are available to consumers during the 2027 Open Enrollment period and will affect 2028 Medicare Advantage quality bonus payments.

The latest CMS figures show:

  • Approximately 37% of MA-PD contracts, or 188 contracts, earned four stars or higher.
  • Approximately 71% of MA-PD enrollees are currently in contracts with four or more stars for 2027.
  • Fifteen MA-PD contracts received five stars.

Star Ratings measure plan performance across quality and service areas. They help beneficiaries compare plans, but they should not replace an examination of individual coverage needs.

New measurement areas

The 2027 Star Ratings include changes to the measures CMS uses to evaluate plans.

Two new measures were added:

  1. Concurrent use of opioids and benzodiazepines.
  2. Polypharmacy involving multiple anticholinergic medications in older adults.

CMS also increased the weight assigned to the Improving or Maintaining Physical Health and Improving or Maintaining Mental Health measures from one to three.

These changes place additional measurement emphasis on specific clinical and medication-related areas.

For agents, the important point is to use the current 2027 rating rather than repeating an older plan rating in marketing materials or consumer conversations.

Also remember that 2027 Star Ratings affect 2028 quality bonus payments. They should not be presented as a guarantee of an individual's healthcare experience.

Source: CMS — 2027 Medicare Advantage and Part D Star Ratings.

6. What Medicare Agents Should Change in Their 2027 Strategy

The latest data points to a more detailed approach to Medicare sales and client retention.

Instead of relying only on broad demographics or national market trends, agencies should build their processes around the beneficiary's actual location, current coverage and individual needs.

Here are six practical priorities.

1. Review plans by county, not just by state

A state-level overview is not enough.

Two beneficiaries in the same state may have very different Medicare Advantage options because plans are offered within defined service areas.

Use current CMS plan information and Medicare Plan Finder to confirm the options available in the beneficiary's county.

2. Identify beneficiaries affected by carrier changes

Review existing client records for plans that are being discontinued, consolidated or changed for 2027.

Do not assume that every affected beneficiary will automatically move to an equivalent plan.

They may need a fresh comparison of providers, prescriptions, costs and coverage.

3. Make prescription reviews part of the conversation

The 2027 Part D deductible and cost-sharing changes make medication details important.

Agents should review the beneficiary's prescriptions, preferred pharmacies, formularies, drug tiers and estimated out-of-pocket costs using current plan information.

A low premium alone is not enough to establish that a drug plan is suitable.

4. Use current Star Ratings

The 2027 Star Ratings are now published.

Agents should use the correct contract rating and explain what it measures. Ratings are one comparison factor alongside networks, cost sharing, prescription coverage and plan availability.

5. Understand why the consumer is shopping

Not every Medicare inquiry has the same motivation.

Some consumers may be:

  • New to Medicare.
  • Reviewing a plan after receiving a coverage notice.
  • Concerned about prescription drug costs.
  • Looking for a different provider network.
  • Comparing Medicare Advantage and Original Medicare.
  • Reviewing coverage after a move.
  • Seeking information about a Special Needs Plan.

Understanding the reason for the inquiry helps agents prepare for a more relevant conversation.

It does not establish eligibility or guarantee that a particular plan is available.

6. Measure the full acquisition and enrollment process

Medicare agencies should avoid judging lead performance only by the number of records received.

Useful operational metrics include:

MetricWhat it helps measure
Speed to first contactHow quickly the team responds
Contact rateHow many opportunities become conversations
Qualified conversation rateHow many conversations meet agreed criteria
Appointment rateHow many conversations lead to appointments
Show rateHow many scheduled appointments take place
Enrollment submissionsHow many applications are submitted
Approved enrollmentsHow many submitted applications are approved
Cost per enrollmentAcquisition cost relative to the resulting enrollment

These measures help agencies identify where their process needs improvement.

A low cost per lead does not automatically mean a low cost per enrollment.

The 2027 Medicare market reinforces the importance of matching consumer interest with the right agency, geography and follow-up process.

A generic Medicare inquiry may not explain why the consumer is shopping or what coverage questions they need to resolve.

For agencies evaluating Medicare lead generation, it is useful to understand the differences between the three common acquisition formats.

Medicare Web Leads

A consumer submits information through a digital experience. The agency generally initiates the first direct sales conversation.

This format can support a structured follow-up process, but agencies should understand delivery timing, consumer expectations, source information and campaign criteria.

Medicare Inbound Calls

The consumer initiates the telephone call after interacting with relevant marketing.

This format requires sufficient phone coverage and a process for handling calls when agents are unavailable.

Medicare Live Transfers

A consumer is connected to an available receiving agent through a transfer or handoff workflow.

The qualification and screening process can vary by campaign, so agencies should confirm the criteria, consumer expectations and transfer conditions before launch.

Questions to ask a Medicare lead provider

Before starting a campaign, agencies should understand:

  • Where does the consumer inquiry originate?
  • What did the consumer respond to?
  • What information is collected?
  • How is consent documented?
  • What qualification criteria apply?
  • Are distribution terms exclusive or shared?
  • How are calls and web leads delivered?
  • What happens when agents are unavailable?
  • What is the applicable return or replacement policy?

The objective should be to understand the opportunity being delivered, not simply purchase the largest possible number of leads.

Freedom Marketing Group provides Medicare web leads, consumer-initiated inbound calls and live transfers for insurance organizations. Campaign availability, qualification criteria, distribution terms and delivery arrangements should be confirmed for the specific campaign.

Explore Medicare leads from Freedom Marketing Group or learn about how FMG generates insurance leads.

The Bigger Picture: Medicare in 2027 Is About Local Market Intelligence

The 2027 Medicare Advantage market cannot be explained by a single headline.

Nationally, CMS projects relatively stable plan availability, lower weighted average Medicare Advantage premiums and approximately 34 million Medicare Advantage enrollees.

At the county level, KFF identifies significant insurer footprint changes, fewer beneficiaries with access to more than 40 MA-PD options and an increase in counties without general-enrollment MA-PD options.

Prescription drug costs and Star Ratings add further complexity.

For Medicare agencies, the opportunity is not to assume that every market is growing or shrinking in the same way. It is to understand the local plan landscape, keep coverage information current and build a process that helps beneficiaries compare their actual options.

In 2027, knowing the Medicare market means knowing more than the national numbers. It means understanding what is happening in the beneficiary's county, what has changed in their coverage and what options are genuinely available.


Sources and Research Methodology

This article uses published 2027 Medicare plan information and research available as of November 7, 2026.

Primary and research sources:

  1. CMS — Medicare Advantage and Medicare Prescription Drug Programs Expected to Remain Stable in 2027
  2. KFF — Medicare Advantage Plan Availability Varies Widely by County for 2027
  3. KFF — Medicare Part D Premiums and Cost Sharing in 2027
  4. Medicare.gov — How Much Does Medicare Drug Coverage Cost?
  5. CMS — 2027 Medicare Advantage and Part D Star Ratings
  6. CMS — 2027 Medicare Advantage and Part D Rate Announcement
  7. CMS — Contract Year 2027 Medicare Advantage and Part D Final Rule

Methodology notes

  • CMS national premium and enrollment figures are projections, not guarantees for individual beneficiaries.
  • KFF county-level availability findings focus on MA-PD plans and exclude several other plan categories, including Special Needs Plans, employer group plans, cost plans and MA-only plans, as specified in its analysis.
  • Carrier county exits and entries refer to MA-PD service-area changes, not necessarily complete company withdrawals from Medicare.
  • KFF's $51 Part D premium estimate assumes current enrollees retain their existing plans. CMS's $36 national projection uses a different enrollment reference point and approach. These figures should not be treated as directly interchangeable.
  • Part D deductibles and out-of-pocket thresholds refer to the defined 2027 benefit parameters; individual plan designs may charge lower deductibles.
  • Plan availability, provider networks, drug formularies, premiums and benefits must be verified for the beneficiary's specific location and circumstances.

Freedom Marketing Group, LLC is not affiliated with or endorsed by Medicare, CMS or any government agency. This article is for general informational and industry-education purposes and is not insurance, medical, legal or compliance advice. Agents should use current CMS, carrier and plan documents when discussing coverage. No lead or call type guarantees eligibility, enrollment or sales.

Frequently Asked Questions

The main trends include changing county-level plan availability, insurer service-area exits and expansions, lower projected national average Medicare Advantage premiums, higher Part D benefit thresholds and updated Star Ratings.

Not as a simple nationwide trend. CMS projects approximately 34 million Medicare Advantage enrollees in 2027, representing about 47.4% of Medicare enrollment. However, individual insurers are changing their county footprints, so local availability differs.

CMS projects approximately 5,532 Medicare Advantage plans nationally. KFF's separate analysis finds an average of 28 Medicare Advantage plans with prescription drug coverage (MA-PDs) available per beneficiary. These figures use different plan definitions.

The standard Part D deductible is $700 in 2027, compared with $615 in 2026. Individual plans may have lower deductibles or no deductible.

The annual out-of-pocket threshold for covered Part D drugs is $2,400 in 2027. After reaching the threshold, beneficiaries receive catastrophic coverage and pay no additional out-of-pocket cost sharing for covered Part D drugs for the remainder of the year.

CMS projects that the weighted average monthly Medicare Advantage premium will decrease from $14.37 in 2026 to $12.00 in 2027. Individual plan premiums can be higher or lower.

Insurers make service-area decisions based on their own market, operational and financial considerations. The reasons vary by company and location. A county exit does not necessarily mean the insurer is leaving Medicare Advantage nationally.

Agents should focus on county-level plan availability, carrier changes, provider networks, prescription coverage, cost sharing, current Star Ratings and the beneficiary's actual coverage needs. Agencies should also track their full lead-to-enrollment process rather than relying only on lead volume.

Agencies can explore FMG Medicare lead options, including web leads, inbound calls and live transfers, and review the FMG lead-generation methodology.

See how our Medicare live transfers and inbound Medicare calls are delivered, screened and routed to your agents.

Explore our lead types